Stocks
Intra-Cellular Therapies Financial Statements (ITCI) |
||||||||||
| Intra-Cellular Therapiessmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.03.2020 | 25.02.2021 | 01.03.2022 | 01.03.2023 | 22.02.2024 | 30.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.061 | 22.5 | 81.7 | 249.1 | 464.4 | 612.9 | |||
| Operating Income, bln rub | -154.0 | -231.2 | -285.7 | -263.6 | -159.4 | -121.6 | ||||
| EBITDA, bln rub | ? | -153.5 | -230.7 | -285.2 | -263.0 | -158.9 | -121.2 | |||
| Net profit, bln rub | ? | -147.7 | -227.0 | -284.1 | -256.3 | -139.7 | -86.4 | |||
| OCF, bln rub | ? | -128.0 | -230.1 | -259.5 | -270.2 | -124.2 | -62.2 | |||
| CAPEX, bln rub | ? | 0.700 | 0.267 | 0.326 | 0.778 | 0.269 | 0.750 | |||
| FCF, bln rub | ? | -128.7 | -230.3 | -259.9 | -271.0 | -124.5 | -62.9 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 154.1 | 251.9 | 359.4 | 492.3 | 590.0 | 687.3 | ||||
| Cost of production, bln rub | 0.477 | 1.90 | 8.03 | 20.4 | 33.7 | 47.3 | ||||
| R&D, bln rub | 89.1 | 65.8 | 88.8 | 134.7 | 180.1 | 216.6 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 7.38 | 0.000 | 4.35 | ||||
| Assets, bln rub | 251.2 | 717.3 | 489.9 | 754.8 | 728.3 | 1 324 | ||||
| Net Assets, bln rub | ? | 195.0 | 656.9 | 417.9 | 656.1 | 591.4 | 1 145 | |||
| Debt, bln rub | 23.1 | 29.1 | 25.4 | 20.0 | 16.9 | 17.7 | ||||
| Cash, bln rub | 224.0 | 657.4 | 412.3 | 591.9 | 497.9 | 1 007 | ||||
| Net debt, bln rub | -200.9 | -628.3 | -386.9 | -571.9 | -481.0 | -988.9 | ||||
| Ordinary share price, rub | 34.3 | 31.8 | 52.3 | 52.9 | 71.6 | 52.3 | ||||
| Number of ordinary shares, mln | 55.2 | 70.4 | 81.3 | 94.0 | 95.9 | 105.8 | ||||
| Market cap, bln rub | 1 893 | 2 238 | 4 253 | 4 977 | 6 867 | 5 536 | ||||
| EV, bln rub | ? | 1 693 | 1 609 | 3 866 | 4 405 | 6 386 | 4 547 | |||
| Book value, bln rub | 195 | 657 | 418 | 656 | 591 | 1 145 | ||||
| EPS, rub | ? | -2.68 | -3.23 | -3.50 | -2.72 | -1.46 | -0.82 | |||
| FCF/share, rub | -2.33 | -3.27 | -3.20 | -2.88 | -1.30 | -0.59 | ||||
| BV/share, rub | 3.53 | 9.34 | 5.14 | 6.98 | 6.17 | 10.8 | ||||
| EBITDA margin, % | ? | -253 303% | -1 024% | -349.0% | -105.6% | -34.2% | -19.8% | |||
| Net margin, % | ? | -243 714% | -1 008% | -347.7% | -102.9% | -30.1% | -14.1% | |||
| FCF yield, % | ? | -6.80% | -10.3% | -6.11% | -5.44% | -1.81% | -1.14% | |||
| ROE, % | ? | -75.8% | -34.6% | -68.0% | -39.1% | -23.6% | -7.54% | |||
| ROA, % | ? | -58.8% | -31.6% | -58.0% | -34.0% | -19.2% | -6.52% | |||
| P/E | ? | -12.8 | -9.86 | -15.0 | -19.4 | -49.2 | -64.1 | |||
| P/FCF | -14.7 | -9.71 | -16.4 | -18.4 | -55.2 | -88.0 | ||||
| P/S | ? | 31 238 | 99.3 | 52.0 | 20.0 | 14.8 | 9.03 | |||
| P/BV | ? | 9.71 | 3.41 | 10.2 | 7.59 | 11.6 | 4.84 | |||
| EV/EBITDA | ? | -11.0 | -6.98 | -13.6 | -16.8 | -40.2 | -37.5 | |||
| Debt/EBITDA | 1.31 | 2.72 | 1.36 | 2.17 | 3.03 | 8.16 | ||||
| R&D/CAPEX, % | 12 725% | 24 663% | 27 275% | 17 316% | 66 967% | 28 881% | ||||
| CAPEX/Revenue, % | 1 156% | 1.18% | 0.40% | 0.31% | 0.06% | 0.12% | ||||
| Intra-Cellular Therapies shareholders | ||||||||||
